Jace Webster
Has grant
Full Specialist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Targeted sequencing of cell-free DNA for monitoring of prostate cancer progression
Open Date: 2021-09-01
Close Date: 2024-08-01
Articles (18)
Circular RNAs (circRNAs) are associated with crucial hallmarks of tumorigenesis. Select circRNAs contain circular open reading frames (cORFs) and impact tumorigenesis through encoded small peptides. However, current circRNA detection approaches bias towards using short-read RNA-seq for detecting circRNA backsplice junctions (BSJs) without reliably reconstructing complete circRNA sequences, inhibiting accurate cORF prediction. To address these challenges, we performed long-read sequencing to enrich for full-length circRNAs that could serve as a guide for short-read alignment. This approach “rescued” circRNAs eluding existing tools focused on circRNA detection from short reads and enabled the development of an open-source bioinformatics workflow that characterizes and rescues circRNAs by integrating short- and long-read RNA-seq: CHRIS (CHaracterizing CircRNAs by Integrative Sequencing). Application of the approach to colorectal cancer (CRC) cell lines and patient samples revealed 6,445 non-canonical isoforms of known circRNAs of which 69 were altered during cancer metastasis. Validation experiments in CRC cell lines confirmed endogenous expression of 11 high-confidence circRNAs rescued by CHRIS. Next, proteogenomic analysis using 67,326 circRNAs detected by CHRIS and mass spectrometry data from 261 CRC patients from Clinical Proteomic Tumor Analysis Consortium (CPTAC) identified 6,848 peptides encoded by circRNAs, including 994 only detectable with long-read integration and 914 potential neoantigens. Overall, this research develops an approach that can facilitate circRNA detection and provide valuable resources for future circRNA tumor biology research.
Year:
2026
Purpose: Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor signaling inhibitors (ARSI) is often lethal. Liquid biopsy biomarkers for this deadly form of disease remain under investigation, and underpinning mechanisms remain ill-understood. Experimental Design: We applied targeted cell-free DNA (cfDNA) sequencing to 126 patients with mCRPC from three academic cancer centers and separately performed genome-wide cfDNA methylation sequencing on 43 plasma samples collected prior to the initiation of first-line ARSI treatment. To analyze the genome-wide sequencing data, we performed nucleosome positioning and differential methylated region analysis. We additionally analyzed single-cell and bulk RNA sequencing data from 14 and 80 patients with mCRPC, respectively, to develop and validate a stem-like signature, which we inferred from cfDNA. Results: Targeted cfDNA sequencing detected AR/enhancer alterations prior to first-line ARSIs that correlated with significantly worse progression-free survival (P = 0.01; HR = 2.12) and overall survival (P = 0.02; HR = 2.48). Plasma methylome analysis revealed that AR/enhancer lethal mCRPC patients have significantly higher promoter-level hypomethylation than AR/enhancer wild-type mCRPC patients (P < 0.0001). Moreover, gene ontology and CytoTRACE analysis of nucleosomally more accessible transcription factors in cfDNA revealed enrichment for stemness-associated transcription factors in patients with lethal mCRPC. The resulting stemness signature was then validated in a completely held-out cohort of 80 patients with mCRPC profiled by tumor RNA sequencing. Conclusions: We analyzed a total of 220 patients with mCRPC, validated the importance of cell-free AR/enhancer alterations as a prognostic biomarker in lethal mCRPC, and showed that the underlying mechanism for lethality involves reprogramming developmental states toward increased stemness. See related commentary by Nawfal et al., p. 7
Year:
2025
Supplementary Figure S11. Cell-free DNA methylation levels of the top 10 least stem-like signature genes in plasma. The box and whisker plots summarize the promoter methylation rates for the top 10 least stem-like genes in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients. p values were calculated by the Student’s t test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.
Year:
2025
Supplementary Figure S7. Distribution of differentially methylated regions in mCRPC plasma cell-free DNA. (A) Distribution of hypomethylated and hypermethylated genic DMRs in pre-treatment plasma cfDNA in AR /enhancer altered lethal mCRPC (compared to AR /enhancer wild-type mCRPC). (B) Genomic annotation of genic DMRs based on their location in the genome. (C) Top 50 hypermethylated DMRs found in pre-treatment plasma cfDNA from AR /enhancer altered lethal mCRPC patients (compared to AR /enhancer wild-type mCRPC). cfDNA, cell-free DNA; CDS, coding sequence; DMRs, differentially methylated regions; mCRPC, metastatic castration-resistant prostate cancer; UTR, untranslated region.
Year:
2025
Supplementary Figure S2. Kaplan-Meier analysis based on plasma collected prior to first-line androgen receptor-signaling inhibitor (ARSI) treatment according to (A,B) Androgen receptor ( AR ) gene body status and (C,D) AR enhancer region status in 63 patients with metastatic castration-resistant prostate cancer (mCRPC). p values were calculated by the log-rank test and hazard ratios (HRs) by the Mantel-Haenszel method.
Year:
2025
Supplementary Figure S10. Cell-free DNA methylation levels of the top 10 most stem-like signature genes in plasma. The box and whisker plots summarize promoter methylation rates for the top 10 most stem-like signature genes in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients. p values were calculated by the Student’s t test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.
Year:
2025
Supplementary Figure S1. Genomic landscape of metastatic castration-resistant prostate cancer (mCRPC) samples profiled using EnhanceAR-Seq. EnhanceAR-Seq, Enhancer and neighboring loci of Androgen Receptor Sequencing.
Year:
2025
Supplementary Figure S4. Summary of alterations in biologically relevant pathways found in pre-ARSI plasma cell-free DNA of 63 metastatic castration-resistant prostate cancer patients. ARSI, androgen receptor-signaling inhibitors.
Year:
2025
Supplementary Figure S9. Cell-free DNA methylation analysis of differentially accessible transcription factor binding sites. The box and whisker plots summarize methylation levels in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients after z-score transformation of the 10,000 TF binding sites corresponding to each of the top 20 TFs that are (A) most accessible and (B) least accessible in cfDNA from AR /enhancer altered lethal high-risk mCRPC patients. p values were calculated by the Mann-Whitney U test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.
Year:
2025
Supplementary Figure S6. Kaplan–Meier survival analysis of the 43-patient mCRPC cohort that also underwent genome-wide EM-seq, according to (A,B) AR /enhancer alteration status and (C,D) median-split ichorCNA-based median tumor fraction. p values were calculated by the log-rank test and hazard ratios (HRs) by the Mantel-Haenszel method. cfDNA, cell-free DNA; mCRPC; metastatic castration-resistant prostate cancer.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2023
Year:
2023
Year:
2023
Collaborators (11)
Oliver Sartor
Tulane University School of Medicine
Sean Park
Professor
Mayo Clinic Rochester
Peter Harris
Staff Scientist
Washington University in St. Louis
Aadel A. Chaudhuri
Washington University School of Medicine
Jacob Orme
Assistant Professor
Mayo Clinic
Pradeep Chauhan
Assistant Professor
Mayo Clinic
Fabrice Lucien
Assistant Professor
Mayo Clinic Minnesota
Russell K. Pachynski
Washington University School of Medicine
jingqin luo
Associate Professor
Washington University in Saint Louis School of Medicine
Christopher A Maher
Washington University in St. Louis
Amy Ly
Staff Scientist
Washington University in St. Louis
Make your next move.
Prepare your application
Review drafts before you send them.